Cargando…

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis

OBJECTIVE: Sarcopenia is characterized by a loss of muscle mass and strength, which leads to frailty and mortality. Rheumatoid arthritis (RA) is considered to be a cause of sarcopenia. The present study assessed the effectiveness of biological disease-modifying antirheumatic drugs (bDMARDs) on sarco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Eriko, Ito, Satoshi, Kurosawa, Yoichi, Kobayashi, Daisuke, Otani, Hiroshi, Abe, Asami, Nakazono, Kiyoshi, Murasawa, Akira, Narita, Ichiei, Ishikawa, Hajime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970816/ https://www.ncbi.nlm.nih.gov/pubmed/36725065 http://dx.doi.org/10.2169/internalmedicine.9600-22

Ejemplares similares

An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2018)

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis
por: Kurosawa, Yoichi, et al.
Publicado: (2022)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

Erratum for Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)

Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis
por: Kobayashi, Tetsuo, et al.
Publicado: (2016)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report
por: Sato, Hiroe, et al.
Publicado: (2014)

An Analysis of the Neuropathic Pain Components in Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2017)

Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2020)

Erratum for Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2021)

Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors
por: Kobayashi, Tetsuo, et al.
Publicado: (2015)

The Combination of Modified Mitchell’s Osteotomy and Shortening Oblique Osteotomy for Patients with Rheumatoid Arthritis: An Analysis of Changes in Plantar Pressure Distribution
por: Lee, Hyunho, et al.
Publicado: (2021)

Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis
por: Sato, Hiroe, et al.
Publicado: (2020)

False‐positive semiquantitative immunochromatography assays for procalcitonin in three patients with rheumatoid arthritis—A case series
por: Sato, Hiroe, et al.
Publicado: (2020)

Circulating levels of carbamylated protein and neutrophil extracellular traps are associated with periodontitis severity in patients with rheumatoid arthritis: A pilot case-control study
por: Kaneko, Chihiro, et al.
Publicado: (2018)

Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports
por: Kobayashi, Tetsuo, et al.
Publicado: (2019)

Giant Cell Arteritis That Presented with Buccal Skin Ulceration along the Facial Artery
por: Hasegawa, Eriko, et al.
Publicado: (2022)

Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis—possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report
por: Habuka, Masato, et al.
Publicado: (2018)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
por: Kuroda, Takeshi, et al.
Publicado: (2016)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
por: Hashimoto, Motomu, et al.
Publicado: (2018)

Adult-onset Chronic Recurrent Multifocal Osteomyelitis with High Intensity of Muscles Detected by Magnetic Resonance Imaging, Successfully Controlled with Tocilizumab
por: Sato, Hiroe, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
por: Sato, Shuzo, et al.
Publicado: (2021)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kppv7vfs8d45opd6ce8lqrra3g